| Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B | Tenofovir alafenamide, Tenofovir disoproxil | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | Nov 18, 2026 |
| An Evaluation of the Potential for VH4011499 Drug-drug-interactions | Efavirenz | Phase 1 | Not yet recruiting | ViiV Healthcare | Nov 16, 2026 |
| People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness | Emtricitabine, Rilpivirine, Tenofovir alafenamide, Tenofovir disoproxil | Phase 1 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Nov 16, 2026 |
| Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide | Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil | — | Recruiting | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Nov 6, 2026 |
| Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV | Emtricitabine, Rilpivirine, Tenofovir alafenamide, Tenofovir disoproxil | Phase 4 | Not yet recruiting | Gilead Sciences | Nov 2, 2026 |
| Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator | Emtricitabine, Tenofovir disoproxil | Phase 4 | Not yet recruiting | University of South Florida | Oct 28, 2026 |
| Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study | Rilpivirine | Phase 4 | Not yet recruiting | University of North Carolina, Chapel Hill | Oct 26, 2026 |
| Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV | Doravirine, Emtricitabine, Lamivudine, Tenofovir alafenamide, Tenofovir disoproxil, Islatravir | Phase 2 | Not yet recruiting | The University of Texas Health Science Center, Houston | Oct 13, 2026 |
| DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg | Doravirine, Islatravir | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | Oct 7, 2026 |
| Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO). | Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil | — | Not yet recruiting | Ente Ospedaliero Ospedali Galliera | Oct 6, 2026 |
| Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels | Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil | Phase 2 | Recruiting | Gilead Sciences | Sep 25, 2026 |
| A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) | Lamivudine | Phase 2 | Not yet recruiting | ViiV Healthcare | Sep 11, 2026 |
| Tenofovir Exposures in Advanced Kidney Disease Study | Emtricitabine, Tenofovir alafenamide | — | Not yet recruiting | King's College Hospital NHS Trust | Sep 10, 2026 |
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa | Abacavir, Lamivudine, Zalcitabine | Phase 3 | Not yet recruiting | University College, London | Aug 28, 2026 |
| Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma | Rilpivirine | Not applicable | Recruiting | Shanghai Public Health Clinical Center | Jul 27, 2026 |
| Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. | Rilpivirine | — | Active, not recruiting | FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE | Jul 14, 2026 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy | Rilpivirine | Phase 3 | Recruiting | Gilead Sciences | Jul 6, 2026 |
| Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up | Lamivudine, Zalcitabine | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | Jul 1, 2026 |
| Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV | Doravirine, Lamivudine, Zalcitabine | Phase 4 | Not yet recruiting | University of Witwatersrand, South Africa | Jun 29, 2026 |
| A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed | Rilpivirine | Phase 3 | Recruiting | ViiV Healthcare | Jun 16, 2026 |
| Lamivudine as a Novel Clinical Effort for Rett Syndrome | Lamivudine, Zalcitabine | Phase 2 | Enrolling by invitation | Maria Denise Fernandes Carvalho de Andrade | Jun 10, 2026 |
| Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study | Rilpivirine | Phase 2 | Recruiting | Beijing 302 Hospital | Jun 10, 2026 |
| Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens | Efavirenz, Lamivudine, Zalcitabine | Phase 4 | Not yet recruiting | Shanghai Public Health Clinical Center | Jun 8, 2026 |
| Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women | Lamivudine, Zalcitabine | Phase 4 | Recruiting | Fundación Huésped | Jun 1, 2026 |
| Drug-Drug Interactions of JMKX003142 in Healthy Participants | Efavirenz | Phase 1 | Not yet recruiting | Jemincare | May 4, 2026 |
| Preliminary Testing and Development of a Short Digital Intervention for Patients on Waiting Lists for Psychological Treatment | Abacavir | Not applicable | Enrolling by invitation | University of Oslo | Mar 30, 2026 |
| Efavirenz for the Treatment of Creutzfeldt-Jakob Disease | Efavirenz | Phase 3 | Recruiting | Xuanwu Hospital, Beijing | Mar 19, 2026 |
| A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment | Zalcitabine | Phase 3 | Recruiting | ViiV Healthcare | Feb 6, 2026 |
| Efficacy and Safety of Doravirine in the Rapid Initiation | Doravirine, Zalcitabine | Phase 4 | Recruiting | Fundación Huésped | Jan 22, 2026 |
| A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants | Efavirenz | Phase 1 | Not yet recruiting | Sunshine Lake Pharma Co., Ltd. | Jan 14, 2026 |
| A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) | Islatravir | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | Dec 5, 2025 |
| Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up | Abacavir | Phase 4 | Recruiting | José Antonio Mata Marín | Aug 22, 2025 |
| Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World | Zidovudine | — | Recruiting | West China Hospital | Aug 6, 2025 |
| Research on the Psychological Status of Patients With HIV-1 Infection | Abacavir, Efavirenz, Nevirapine, Zidovudine | — | Not yet recruiting | Shanxi Bethune Hospital | Jul 23, 2025 |
| DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity | Doravirine | Phase 3 | Recruiting | José Antonio Mata Marín | Jul 20, 2025 |
| Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention | Dapivirine | Phase 4 | Recruiting | University of Alabama at Birmingham | Jul 20, 2025 |
| Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan | Abacavir | Not applicable | Recruiting | Pakistan Institute of Living and Learning | Jun 11, 2025 |
| Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | Zidovudine | Phase 2 | Recruiting | Novartis Pharmaceuticals | Apr 27, 2025 |
| STI Testing to Enhance PrEP Use in Pregnancy | Dapivirine | Phase 3 | Recruiting | Botswana Harvard AIDS Institute Partnership | Apr 9, 2025 |
| A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) | Islatravir | Phase 2 | Active, not recruiting | Merck Sharp & Dohme LLC | Mar 24, 2025 |
| The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY | Efavirenz | Not applicable | Recruiting | University of Toronto | Feb 12, 2025 |
| PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa. | Dapivirine | — | Recruiting | Desmond Tutu HIV Foundation | Feb 4, 2025 |
| Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully | Doravirine | Phase 2 | Recruiting | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Jan 14, 2025 |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 | Abacavir, Doravirine, Islatravir | Phase 3 | Active, not recruiting | Gilead Sciences | Oct 8, 2024 |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 | Islatravir | Phase 3 | Active, not recruiting | Gilead Sciences | Oct 8, 2024 |
| PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women | Dapivirine | Not applicable | Recruiting | Massachusetts General Hospital | Aug 22, 2024 |
| STARLITE for Unresectable High-Grade Gliomas | Abacavir | Phase 1 | Recruiting | University of Miami | May 24, 2024 |
| Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus | Abacavir | Phase 2 | Not yet recruiting | Hospices Civils de Lyon | Apr 10, 2024 |
| Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses | Doravirine, Efavirenz, Etravirine | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | Apr 1, 2024 |
| A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments | Didanosine, Nevirapine, Stavudine, Zidovudine | Phase 4 | Recruiting | Gilead Sciences | Mar 29, 2024 |
| Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT | Dapivirine | Phase 3 | Recruiting | Africa Health Research Institute | Feb 9, 2024 |
| B-free Multistage Trial | Etravirine | Phase 4 | Enrolling by invitation | Insel Gruppe AG, University Hospital Bern | Sep 14, 2023 |
| A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) | Islatravir | Phase 3 | Active, not recruiting | Merck Sharp & Dohme LLC | Mar 13, 2023 |
| DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | Islatravir | Phase 3 | Active, not recruiting | Merck Sharp & Dohme LLC | Jan 30, 2023 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) | Delavirdine, Nevirapine, Zidovudine | Phase 2 / Phase 3 | Active, not recruiting | Gilead Sciences | Aug 16, 2022 |
| Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | Zidovudine | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Apr 22, 2019 |
| Early Infant HIV Treatment in Botswana | Nevirapine, Zidovudine | Phase 2 / Phase 3 | Active, not recruiting | Harvard School of Public Health (HSPH) | Feb 24, 2015 |
| Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission | Nevirapine | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | May 16, 2014 |
| Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV | Delavirdine, Didanosine, Etravirine, Nevirapine, Stavudine, Zidovudine | Phase 2 / Phase 3 | Active, not recruiting | Gilead Sciences | Dec 20, 2013 |